Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?

Ten Cate DF, Jacobs JWG, Swen WAA, Hazes JMW, de Jager MH, Basoski NM, Haagsma CJ, Luime JJ, Gerards AH.

Arthritis Res Ther. 2018 Jan 30;20(1):15. doi: 10.1186/s13075-018-1514-2.

2.

Modification of a sonographic enthesitis score to differentiate between psoriatic arthritis and young healthy volunteers.

Wervers K, Vis M, Rasappu N, van der Ven M, Tchetverikov I, Kok MR, Gerards AH, Hazes J, Luime JJ.

Scand J Rheumatol. 2018 Jan 2:1-4. doi: 10.1080/03009742.2017.1393695. [Epub ahead of print]

PMID:
29291671
3.

Absence of ultrasound inflammation in patients presenting with arthralgia rules out the development of arthritis.

van der Ven M, van der Veer-Meerkerk M, Ten Cate DF, Rasappu N, Kok MR, Csakvari D, Hazes JMW, Gerards AH, Luime JJ.

Arthritis Res Ther. 2017 Sep 15;19(1):202. doi: 10.1186/s13075-017-1405-y.

4.

Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.

Lamers-Karnebeek FB, Luime JJ, Ten Cate DF, Teerenstra S, Swen NWAA, Gerards AH, Hendrikx J, van Rooyen EM, Voorneman R, Haagsma C, Basoski N, de Jager M, Ghiti Moghadam M, Efde MN, Goekoop-Ruiterman YPM, van Riel PLCM, Jacobs JWG, Jansen TL.

Rheumatology (Oxford). 2017 Sep 1;56(9):1560-1565. doi: 10.1093/rheumatology/kex184.

PMID:
28595367
5.

No clear association between ultrasound remission and health status in rheumatoid arthritis patients in clinical remission.

van der Ven M, Kuijper TM, Gerards AH, Tchetverikov I, Weel AE, van Zeben J, Hazes JM, Luime JJ.

Rheumatology (Oxford). 2017 Aug 1;56(8):1276-1281. doi: 10.1093/rheumatology/kex080.

PMID:
28407127
6.

Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.

de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.

Rheumatology (Oxford). 2016 Dec;55(12):2138-2147. Epub 2016 Aug 30.

PMID:
27581208
7.

Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.

Kuijper TM, Luime JJ, de Jong PH, Gerards AH, van Zeben D, Tchetverikov I, de Sonnaville PB, van Krugten MV, Grillet BA, Hazes JM, Weel AE.

Ann Rheum Dis. 2016 Dec;75(12):2119-2123. doi: 10.1136/annrheumdis-2016-209272. Epub 2016 Jun 9.

PMID:
27283332
8.

Do we need to lower the cut point of the 2010 ACR/EULAR classification criteria for diagnosing rheumatoid arthritis?

van der Ven M, Alves C, Luime JJ, Gerards AH, Barendregt PJ, van Zeben D, van Schaeybroeck B, de Sonnaville PB, Grillet BA, Hazes JM.

Rheumatology (Oxford). 2016 Apr;55(4):636-9. doi: 10.1093/rheumatology/kev383. Epub 2015 Nov 4.

PMID:
26538422
9.

Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study.

Markusse IM, Dirven L, Gerards AH, van Groenendael JH, Ronday HK, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2015 Aug 31;17:232. doi: 10.1186/s13075-015-0730-2.

10.

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.

de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, van Schaeybroeck B, de Sonnaville PB, van Krugten MV, Luime JJ, Weel AE.

Ann Rheum Dis. 2014 Jul;73(7):1331-9. doi: 10.1136/annrheumdis-2013-204788. Epub 2014 May 1.

11.

Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis.

de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Ćalasan MB, Weel AE, Huisman AM, Gerards AH, van Schaeybroeck B, Wulffraat NM, Lindemans J, Hazes JM, de Jonge R.

Ann Rheum Dis. 2015 Feb;74(2):408-14. doi: 10.1136/annrheumdis-2013-203725. Epub 2013 Dec 2.

PMID:
24297383
12.

Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.

van der Heijden JW, Assaraf YG, Gerards AH, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G.

Scand J Rheumatol. 2014;43(1):9-16. doi: 10.3109/03009742.2013.797490. Epub 2013 Aug 30.

PMID:
23987246
13.

Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis--a systematic review of the literature.

Ten Cate DF, Luime JJ, Swen N, Gerards AH, De Jager MH, Basoski NM, Hazes JM, Haagsma CJ, Jacobs JW.

Arthritis Res Ther. 2013 Jan 8;15(1):R4. doi: 10.1186/ar4132. Review.

14.

Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study.

de Jong PH, Quax RA, Huisman M, Gerards AH, Feelders RA, de Sonnaville PB, Luime JJ, Weel AE, Hazes JM.

Ann Rheum Dis. 2013 Oct;72(10):1659-63. doi: 10.1136/annrheumdis-2012-202152. Epub 2012 Oct 31.

PMID:
23117243
15.

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.

de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.

Ann Rheum Dis. 2013 Jan;72(1):72-8. doi: 10.1136/annrheumdis-2011-201162. Epub 2012 Jun 7.

PMID:
22679301
16.

Brief Report: to squeeze or not to squeeze, that is the question! Optimizing the disease activity score in 28 joints by adding the squeeze test of metatarsophalangeal joints in early rheumatoid arthritis.

de Jong PH, Weel AE, de Man YA, Huisman AM, Gerards AH, van Krugten MV, Luime JJ, Hazes JM.

Arthritis Rheum. 2012 Oct;64(10):3095-101. doi: 10.1002/art.34568.

17.

Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up.

van den Broek M, Dirven L, de Vries-Bouwstra JK, Dehpoor AJ, Goekoop-Ruiterman YP, Gerards AH, Kerstens PJ, Huizinga TW, Lems W, Allaart CF.

Ann Rheum Dis. 2012 Sep;71(9):1530-3. doi: 10.1136/annrheumdis-2011-201212. Epub 2012 Apr 24.

PMID:
22532630
18.

Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.

Klarenbeek NB, Koevoets R, van der Heijde DM, Gerards AH, Ten Wolde S, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2011 Oct;70(10):1815-21. doi: 10.1136/ard.2010.149260. Epub 2011 Aug 3.

PMID:
21813548
19.

Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.

Güler-Yüksel M, Klarenbeek NB, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van der Kooij SM, Gerards AH, Ronday HK, Huizinga TW, Dijkmans BA, Allaart CF, Lems WF.

Arthritis Res Ther. 2010;12(3):R96. doi: 10.1186/ar3025. Epub 2010 May 20.

20.

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial.

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA.

Arthritis Rheum. 2008 Feb;58(2 Suppl):S126-35. doi: 10.1002/art.23364.

Supplemental Content

Loading ...
Support Center